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Mohammad Burhan Uddin1 and Md Moklesur Rahman Sarker3Abstract
Background: Present study describe the in vitro model of plasma oxidation of patients with different lipid profile,
that can be correlated to their invivo plasma oxidizability in order to find the arterial diseases prone patient groups.
Method: The method applied here to measure the invitro plasma oxidizability, accounts a convenient way that can
be well suited in any clinical laboratory settings. Un-fractionated plasma was exposed to CuSO4 (5.0 mmol/L), a
pro-oxidant, and low frequency ultrasonic wave to induce oxidation, and finally oxidizability was calculated by
TBARS and Conjugated Diene methods.
Result: In our study, plasma LDL greater than 150 mg/dL possess 1.75 times more risk to undergo oxidation
(CI, 0.7774 to 3.94; p = 0.071) than the low LDL plasma, percent of oxidation increased from 38.3% to 67.1% for the
LDL level upto 150 mg/dL and high. Lag phase, which is considered as the plasma antioxidative protection, was
also influenced by the higher LDL concentration. The mean lag time was 65.27 ± 20.02 (p = 0.02 compared to
healthy), where as for 94.71 ± 35.11 min for the normolipidemic subject. The plasma oxidizability was also changed
drastically for total cholesterol level, oxidative susceptibility shown 35% and 55.02% for 200 mg/dL and high
respectively, however it didn’t appear as risk factor. Patient samples were also stratified according to their age,
gender, and blood glucose level. Older persons (≥40 years) were 1.096 times (95% CL, 0.5607 to 2.141, p = 0.396)
than younger (≤39 years age), males are 1.071 (95% CI, 0.5072- 2.264) times than the females, and diabetic patients
are 1.091 (CI, 0.6153 to 1.934, p = 0.391) times in more risk than the non-diabetic counterpart.
Conclusion: This method addressing its easy applicability in biomedical research. And by this we were able to
show that patients with high LDL (≥150 mg/dL) are in alarming condition besides diabetic and elderly (≥40 years
age) males are considered to be susceptible and more prone to develop vascular diseases.
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The clinical importance of lipid oxidation, mainly low
density lipoproteins (LDLs) is presumably associated
with atherosclerosis formation [1]. Though in biological
model it is not easy to show the pathological process of
atherosclerosis, however the in vitro oxidizability of
patients’ plasma could be extrapolated to assess the sus-
ceptible patient group [2]. Many studies has shown the* Correspondence: hasan.imam@primeasia.edu.bd
1Department of Pharmacy, Primeasia University, 9 Banani C/A, Dhaka 1213,
Bangladesh
Full list of author information is available at the end of the article
© 2014 Imam et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Cu2+ mediated oxidation of isolated LDL and fatty acids
[2-4], even in unfractionated plasma [2]. We have exer-
cised here also the same protocol to study the unfrac-
tionated plasma in the presence of CuSO4, but there
was not enough differences observed in plasma lipid oxi-
dation between presence and absence of CuSO4 alone.
We made a slight modification by exposing them in
ultrasonic wave so that the lipid portion in the solution
would be favorable in size to undergo the oxidative
modification.
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were not previously affected, and newly appearance of
coronary artery disease in recognized CHD patients
[9-11]. From their results it appeared that the level
above 100 mg/dL of LDL cholesterol is atherogenic. In
contrast, it also shown that people with low level of
cholesterol are less prone to develop atherosclerosis and
CHD [12-14]. So there is a positive relationship observed
between serum cholesterol level and CHD. But the
threshold level for this relationship is not very much
straightforward. Again some populations were free from
CHD by maintaining below 150 the total cholesterol or
below 100 mg/dL LDL cholesterol level [15-18]. In case
of higher cholesterol level with young adults were found
increased chances to develop CHD in later stage of their
life [19,20]. On the other hand, low HDL level also
posses the risk of developing CHD, though it holds the
independent relationship. In genetically modified animal
model, it appears that the higher level of HDL protects
it against atherogenesis [21-23] and deficiency of HDL
exacerbates it [24,25]. Moreover the antioxidant and
anti-inflammatory effect of HDL can also impart the
anti-atherogenic role [26,27]. So, there is a lot of pub-
lished work to support the role of lipoproteins on oxi-
dative stress but the oxidative susceptibility status with
different types of lipoproteins and cholesterol levels in
patient’s plasma has not been studied in detail.
To address the susceptibility value of patients’ unfrac-
tionated plasma lipid in terms of their plasma lipid pro-
file as a prototype for the ex vivo lipid oxidation, we
have developed a very convenient and less equipped
model to assess data in large scale. We hypothesized that
plasma lipid oxidizability would be sensitive with the fol-
lowing parameters: level of lipoproteins, cholesterol, tri-
glycerides, age, diabetes mellitus and sex. In order to test
this hypothesis, we carried out three studies- firstly we
examined the plasma lipid profile and then in vitro
plasma lipid oxidation following conjugation diene for-
mation and TBARS formation, in the presence of Cu++
ion with occasional exposure of ultrasonic wave.
Methods
Sample collection
Study subjects included 45 male and female (35 – 75 years
old). Among them, 19 were with LDL level was higher than
100 mg/dL, 14 individuals with greater than 150 mg/dL
level of total cholesterol, 18 individuals with lower than
35 mg/dL of HDL, number of young patients (age below
40 years) were 23 and older (above 40 years) 22, whereas
patients with diabetes mellitus were 15. Peripheral venous
blood samples of all patients’ were collected on heparin
(5 U/ml) from subjects with 12 hours fasting. Plasma was
separated by 5 min centrifugation at 4000 rpm immediately
after collection. Data acquisition were completed on thesame day, alternatively, the samples were stored at 4°C for
24 hours or at −20°C for not more than 2 days. Informed
consent form was made and approved according to
the recommendation of the University Medical Research
Ethical Committee of the Faculty of Science, Primeasia
University, Dhaka, Bangladesh, where the objective of this
study and use of biological samples were clarified.
Biochemical analysis
Blood glucose, total cholesterol (TC), triglyceride (TG)
and HDL level were estimated following the standard la-
boratory methods using 3000-Evolution analyzer (Italy).
And Friedewald’s formula [28] was applied for LDL
estimation.
Plasma oxidizability measurement following
thiobarbituric acid reactive substance formation (TBARS)
method
TBARS formation was measured following the method
described by Adriana E Scoccia [3], malonaldihyde, a se-
condary metabolite and a marker of lipid peroxidation
and oxidative stress, which reacts with Thiobarbituric Acid
(TBA) to yield pink colored complex that can be mea-
sured spectophotometrically. Briefly, 50 μL plasma was
diluted in 10 mL CuSO4 (5.0 mmol/L)solution and incu-
bated at 37°C for 3 hours in ultrasonic waterbath with
occasional exposure of ultrasonic wave (SonoSWISS SW6
H, Switzerland) to allow the oxidation process. Then
0.5 mL of 0.78% aqueous solution of thiobarbituric acid
and 50 μL of acetic acid was added in 0.5 mL of the
plasma-CuSO4 mixture. Control was prepared in the
same way except CuSO4. The mixture was heated at 80°C
for 40 min in a ultrasonic waterbath and absorbances were
taken at 532 nm using a spectrophotometer (SHIMADZU
UV 1650 pc, UV–vis. Spectrophotometer, Japan). Percen-
tage of oxidation was calculated as follows-
Oxidation %ð Þ ¼ Aps−Acð Þ:100=Ac
Where Aps is the absorbance of plasma sample, Ac is
absorbance of control.
Plasma oxidizability measurement following conjugated
diene method
Conjugated diene was measured following a slight modifi-
cation of the method described by Kontush and Beisiegel
[29], where photometrical detection is employed for the
conjugated diene. In brief, 50 μL plasma was diluted to
10 mL phosphate-buffered saline, to which CuSO4 was
added to make the concentration 5.0 mmol/L. In another
tube, 5.0 mmol/L CuSO4 in phosphate-buffered saline
was served as a blank. Samples, in cuvettes, after a brief
exposure of ultrasonic wave were incubated in spec-
trophotometer (SHIMADZU UV 1650 pc, UV–vis.
Figure 1 Comparative oxidation of unfractionated plasma by
incubating in two different conditions at 37°C, here SSWB
means Sono Swiss water bath with ultrasonic wave exposure,
and NWB means normal water bath. Bars are presented; mean
(absorbance) ± SD. Difference in oxidation of plasma between
presence and absence of Cu2+ in ultrasonic bath was significant.
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absorbance was measured at 234 nm in every 2 min inter-
val. Lag phase was considered for the time taken with no
increment of absorbance before a rapid oxidation. The
duration of lag phase indicate the resistance to oxidation.
CDmax was calculated from the maximum absorbance
value and the Beer-Lambert law, where the extinction co-
efficient for conjugated diene is 29500 L.mol/cm [4].Figure 2 Plasma oxidizability with different plasma profile. (A) Plasma
terms of different LDL concentration, which was significantly higher in plasma
level (p = 0.007). (C) Plasma oxidizability of different samples with different HDStatistical analysis
Results are presented as interquartile ranges or as means ±
SDs. Statistical analysis between normal and test group
was performed using Microsoft Excel 2007 and data were
compared with unpaired two tailed t-test. Risk ratio within
95% confidence interval was calculated using Openepi_37V
software (www.openepi.com). Mid p-exact was taken,
where p value threshold was used ≤0.05 to indicate a statis-
tical significant.
Result and discussion
In this in vitro Cu++ and ultrasonic wave mediated oxi-
dative susceptibility assay, first we compared the TBARS
level by incubating tube containing patients’ plasma with
CuSO4 at 37°C in normal waterbath for 3 hours. Having
not any comparable data between treated and untreated
sample, we slightly modified the method by exposing
ultrasonic wave during this incubation period and a
comparable data was generated (Figure 1). This modified
method for TBARS assay was exercised throughout the
experiment. We observed the percent oxidizability in
terms of plasma cholesterol level (Figure 2A) for the first
two subgroups were fairly similar, 36.95% and 35.60% re-
spectively for plasma below 150 and 150-200 mg/dL, but
it jumped to 55.02% for the patients with higher than
200 mg/dL, although not significantly (p = 0.124) com-
pared to the oxidative susceptibility of 150 mg/dL. How-
ever, the risk ratio appeared not so high, 1.003.
Similar trend was observed comparing the plasma
LDL level, which appeared as 32.70 and 38.30% in case
of 100 mg/dL and 100-150 mg/dL subgroup, respectively
compared to the control. But it rose as high as 67.18
percent for LDL level ≥150 mg/dL, which was statisti-
cally significant compared to the other two subgroups
(Figure 2B. p-values were 0.007 for both cases). This
result was supported by the findings of other group’soxidizability in terms of total cholesterol level. (B) Plasma oxidizability in
with highest LDL level than intermediate level (p = 0.0068) and lower
L level. Oxidizability is shown by mean (percent of basal) ± SD.
Table 1 Plasma oxidative susceptibility in different traits






Gender Male 21 42.405 ± 21.53 0.0544 ± 0.002 1.071 (in male than females, p = 0.432) 0.5072 to 2.264
Female 24 43.137 ± 26.95 0.059 ± 0.005
Age Younger
(age below 40 years)
23 29.375 ± 20.13 0.0545 ± 0.0032 1.096 (in older than younger, p = 0.39) 0.5607 to 2.141
Older
(above 40 years)
22 54.336 ± 22.25 0.0575 ± 0.004
Diabetes No 30 28.375 ± 19.56 0.0565 ± 0.0032 1.091(in non-diabetes than diabetes, p = 0.39) 0.6153 to 1.934
Yes 15 38.607 ± 18.61 0.0573 ± 0.0053
Figure 3 Box plot of lag-time in conjugated diene assay. The
boxplot shows variable range of Lag time in conjugated diene assay,
median values were 86.00, 82.00, 72.00 and 62.00 for healthy, patient
group with less than 35mg/dL HDL, greater than 150 mg/dL
cholesterol and ≥100 mg/dL LDL level, with average values 94.71,
88.72, 71.25 and 65.27 respectively.
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creased with increasing volume of LDL. And the risk
ratio demonstrate that higher LDL level indulge patients
in a condition which is 1.75 times more likely to occur
arterial diseases than the low LDL level; the 95% con-
fidence interval around this estimate is 0.7774, 3.94
(p = 0.071).
In Figure (2C) the bar chart compares the serum
oxidative susceptibility in terms of their plasma HDL
concentration. The mean susceptibility was 47.04 and
37.05% for the people with less than 35 and greater that
35 mg/dL of HDL level in their serum.
People with diabetes mellitus were shown to possess
higher plasma oxidizability by both TBARS and CDmax
result (Table 1), and are 1.091 time more in chance to
develop arterial disease than the non-diabetic group,
with a 95% confidence interval of 0.6153 to 1.934.
An analysis between male and female and between
younger (age below 40) and older (above 40) (Table 1),
not considering their diabetes status, showing that the
risk ratio for males is 1.071 (95%, CI 0.5072- 2.264) and
for older is 1.096 (0.5607 to 2.141). But none of these re-
sults were statistically significant.
There is not much differences are showing in plasma
oxidizability between male and female in terms of their
TBARS formation. However, it gave statistically signifi-
cant difference in conjugated diene formation. Turning
to the reasons for the higher value to CDmax, there were
almost half of the women in the presented data were
hyperlipidemic. A circuitous role of oxygen free radical
formation from polymorphonuclear leukocytes and
monocytes in hyperlipidemic subject have previously
been described [30].
Mean lag phase are declined in patients with high LDL
and total plasma cholesterol level (Figure 3). The down-
ward shift, presented in lag phase with LDL and total
cholesterol level higher than 100 and 150 mg /dL, are
statistically significant (p = 0.02 and 0.05, respectively,
compared to healthy volunteer who were normolipide-
mic). Antioxidant defense, attributed mainly by the lipo-
philic antioxidant vitamin E, and other vitamins playrole in the lag phase, which is increased by the presence of
these vitamins [2,31]. Surprisingly, the mean lag phase of
patients with low HDL level are shown to possess high
values. The upward shift is present at even the higher
(75th) percentile in case of HDL value ≤35 mg/dL. Thus,
the upward shift of lag phase in ≤35 mg/dL HDL level is
not solely attributed to the lower amount of HDL present
in the plasma but must have resulted from the influence
of other parameters.
No doubt the lowering of LDL and total cholesterol
should be the primary goal for patients with CHD, but it
could be beneficial knowledge for general patients’ if
their plasma lipid oxidizability values are explained in a
simpler way. Unlike the other methods where fractioning
LDL or HDL by ultracentrifugation, dialysis, electro-
phoresis etc. need much effort. Also the oxidation study
with isolated lipoproteins may raise question about it’s
in vivo comparability [2]. Again this method offers a easy
alternative, and substantial data can be generated with
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which is clinically relevant. The increase in TBARS and
reduction in CD indicating the less antioxdative protec-
tion and high oxidative stress. Data might be influenced
by dietary and drug treatment, since the history were not
taken. However, standardized experimental condition in-
cluding randomization, minimum delaying in data acquisi-
tion and triplicate sampling outweigh possible obstacles.
We conclude that patients with high LDL (≥150 mg/dL)
are in alarming condition besides diabetic patients, and
elderly (age above 40 years) males are considered to be
susceptible and more prone to develop vascular diseases.
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